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ABSTRACT 
Cholera still represents a major public health problem in devel- 
oping countries, and it is associated with significant morbidity 
and mortality in spite of the fact that more is known about its 
epidemiology, pathophysiology, and treatment than is known 
concerning any other diarrhea1 illness. During the past 5 years 
cholera has gained the attention of the scientific community 
because of three events: the extension of the seventh pan- 
demic of El Tor V&io cholerae 01 to South and Central Amer- 
ica in 1991; the appearance of a novel non-01 V: cholerae, 
referred to as \/: cholerae 0139 or “Bengal” strain in October 
1992 in India and Bangladesh; and the explosive epidemic of 
multiple-resistant K cholerae 01 El Tor among Rwandan 
refugees in Zaire in 1994, with the highest mortality ever 
reported. This report presents data on recent epidemics of 
cholera, focusing on epidemiologic, clinical, therapeutic, and 
preventive issues. Lessons learned from these epidemics 
should help researchers to prevent or control future epidemics, 
More effective vaccines than are currently available, with broad 
coverage against new agents, clearly are needed. 
Key Words: antimicrobial, cholera, cholera vaccines, 
diarrhea/ diseases. Vibrio cholerae 
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Cholera is the most feared of all diarrhea1 diseases in his- 
tory Few infectious diseases can influence so negatively 
the economy of developing countries as cholera does. 
Even nowadays, more than 100 years after the identifi- 
cation of its route of acquisition and the discovery of its 
causative agent, cholera is still associated with significant 
morbidity and mortality in developing countries in spite 
of the fact that more is known about its pathophysiology 
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and treatment than is known concerning any other 
diarrheal illness. The concept by which cholera was con- 
sidered a predictable disease has been challenged 
recently, as new areas of the globe are becoming affected, 
such as South and Central America.’ Devastating epi- 
demics of VWio cbolerae 01 have occurred in Zaire,’ 
multiple-resistant strains of Rcholerae 01 are becoming 
prevalent in Bangladesh and India,3 and finally, a new 
agent, K cholerae 0139, with pandemic potential 
appeared in 1993 in India and Bangladesh.* 
This report presents data from recent epidemics of 
Kcholerae 01 El Tor in South America and Africa, as 
well as data on the more recent epidemic of Vcbolerae 
0139 in Asia, focusing on epidemiologic, clinical, and 
preventive issues. 
EPIDEMIOLOGIC ASPECTS 
Since 1817, seven pandemics of cholera with worldwide 
extension have been recorded.5 The first six pandemics 
of cholera originated in the Indian subcontinent and were 
caused by the classic biotype of R cholerae 0l.j The 
most recent pandemic of R cholerae 01 has a number 
of differences from the previous six pandemics; it was 
produced by the serotype El Tor instead of the classic 
serotype. It originated in Indonesia instead of the Indian 
subcontinent; it is the largest pandemic in terms of geo- 
graphic area and number of people affected; and it is the 
longest pandemic ever recorded, lasting more than 34 
years since its beginning in 1961. The latter can be 
explained by the increased ability of the El Tor biotype 
to survive in the environment compared to the classic 
biotype, and the high proportion of asymptomatic car- 
riers of R cholerae observed during epidemics caused 
by this serotype. These carriers can easily spread the dis- 
ease to distant places from the initial focus.6 
During the past 5 years, cholera has gained the atten- 
tion of the scientific community, basically due to three 
events: (1) the extension of the seventh pandemic of El Tor 
Vcholeme 01 to South and Central America in 1991,’ (2) 
the appearance of a novel non-01 Rcholerae, referred to 
as Vcholerae 0139 or the “Bengal” strain, with pandemic 
potential, in October 1992 in India and Bangladesh,* and 
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(3) the explosive epidemic of multiple-resistant Vcholerue 
01 El Tor among Rwandan refugees in Zaire in 1994, with 
the highest mortality ever reported.2 Additionally, imported 
cases of cholera from these areas into developed coun- 
tries have been reported.7-9 
The Latin American Extension 
of the Seventh Cholera Pandemic 
The Latin American extension of the seventh cholera pan- 
demic is probably the best-documented epidemic of 
cholera in recent years. The epidemic started during the 
last week of January 199 1, almost simultaneously, in three 
coastal cities of Peru.’ El Tor Rcholerae 01 serotype 
Inaba was isolated from stool samples of patients with 
severe dehydration at the Peruvian National Institute of 
Health and confirmed at the Centers for Disease Control 
and Prevention by February 1991.” The epidemic spread 
rapidly not only within Peru but also to other Latin Amer- 
ican countries. By March 1991, cases with cholera had 
been reported from the three natural regions in Peru; the 
coast, the Andean valleys, and the Amazon forest, and 
83% of the Peruvian departments reported cases by the 
fifth week of the epidemic. Other Latin American coun- 
tries were involved in the epidemic at a rate of almost one 
country per month, by the end of 1993 the majority of 
them had reported cases with the exception of Uruguay.” 
Figure 1 illustrates the spread of the cholera pandemic 
among Latin American countries. 
Peru was definitely the most severely affected coun- 
try with 322,562 cases during the first year of the epi- 
demic, representing 82% of the total number of cases 
reported from Latin America to the Pan American Health 
* initial epidemics: 
January 1991 
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Figure 1. The spread of the Latin American epidemic of cholera. 
From Center for Disease Control,11 with permission. 
Organization.11~12 From January 1991 to September 1994, 
Peru had reported 625,259 cases, representing 60% of 
the total number of cholera cases reported in the region.” 
The total number of deaths reported during that period 
was 9642. Approximately 46% of these death cases 
occurred in Peru, but the case fatality rate for Peru was 
the lowest during that period: 0.7%.11 
The evolution of the cholera epidemic in Peru from 
1991 to 1995 is presented in Figure 2. Incidence rates 
(per 100,000 habitants) have shown a trend to decline 
from 1436.55 at the beginning of the epidemic to 69.0 
during the first 4 months of 1995. Epidemiologic studies 
conducted in Peru at the beginning of the epidemic 
showed consistently high attack rates, low case fatality 
rates, and high proportion of acute diarrhea1 cases being 
caused by I? cholerae 0 1. 13-i6 A study conducted during 
February and March 1991 in Trujillo, a northern city of 
Peru, showed attack and case fatality rates of 2.6% and 
0.4%, respectively.13 In that study, Rcholerue 01 was iso- 
lated from 79% of patients with severe dehydration who 
presented at a local hospital.13 In another study, K 
cholerae 01 was isolated from 79% of adult patients who 
presented at a local hospital in Piura during March 1991 
with acute watery diarrhea irrespective of the degree of 
dehydration. I4 Additionally, 34% of asymptomatic people 
showed serologic evidence of being exposed to V 
cholerae during the study period. Similar figures were 
reported from a study conducted in Trujillo during 199 1: 
88% of cases with acute diarrhea observed at two local 
hospitals were attributable to Rcholerae 01, with a shift 
in the serotype from Inaba at the beginning of the epi- 
demic to Ogawa during the study. I6 The Peruvian Gen- 
eral Office of Epidemiology estimated that the ratio of 
asymptomatic to symptomatic cases was around 20 dur- 
ing the beginning of the epidemic.” Lower attack and 
case fatality rates were observed in coastal than in Andean 
and Amazon cities in Peru.15 For instance, attack and case 
fatality rates in villages 5 hours distant from Iquitos, the 
capital of the Peruvian Amazon forest, were 6% and 13.5% 
during May and June 1991, in contrast with national fig- 
ures of 1 to 2% and l%, respectively.” 
Surveillance of bacterial pathogens associated with 
acute diarrhea conducted from December 1992 to March 
1993 in a suburban area of Lima, the capital of Peru, 
showed that R cholerae 01 accounted for 31% of the 
cases, with an estimated attack rate of 2.2 cases per 1000 
for the total population. l* Isolation rates for Rcholerae 
01 were higher in adults than in children in that study 
(41% vs. I6%, P = O.OOl), a pattern consistent with the 
recent introduction of cholera in that community. Sur- 
veillance conducted among adults who presented at a 
large university hospital in Lima seeking care for acute 
diarrhea from February to April 1994 showed that V 
cbolerae 01 accounted for nearly 50% of the cases, with 
watery diarrhea and severe dehydration as the best pre- 
dictors of a cholera case.19 
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TOTAL NUMBER OF CASES/CUMULATIVE 
INCIDENCE BATES (x 100,000) 
1991:322,562cases/1,436.55 
1992:239,139cases/l,o65.62 
1993: 62,326casesl 277.57 
1994: 23,667cases/ 105.47 
1995: 15,626~/ 69.60 i 
Figure 2. Evolution of the cholera epidemic in Peru. Weekly incidence rates from 1991 to the 
first 18 weeks of 1995 are presented. A trend toward a decline in these rates as the epidemic pro- 
gresses is clearly observed. Total number of cases per year and cumulative incidence rates are 
presented. Source: National Office for Epidemiology. Peruvian Health Ministry. 
Both waterborne and foodborne transmission were 
documented in Peru (Table 1). Case-control studies con- 
ducted at the beginning of the epidemic in Piura identi- 
fied the following independent risk factors to acquire 
cholera in multivariate analysis: drinking unboiled water, 
drinking beverages from street vendors, and introducing 
hands into drinking water storage vessels.‘* In contrast, 
drinking boiled water was protective against acquiring 
cholera.‘* Eating raw seafood (cebiche) was identified as 
a risk factor to contract cholera only during the first few 
months of the epidemic. After the massive campaign 
against its consumption, promoted by the Peruvian Min- 
istry of Health, this association could no longer be found. 
Eating unwashed fruits and cool rice, and drinking 
unboiled water were associated with cholera in a case- 
control study in the Amazon f0rest.l’ Drinking local acidic 
beverage was protective in that study. In another study, 
adding ice made from contaminated water to local bev- 
erages was associated with cholera.‘* Waterborne trans- 
mission as the main route of acquisition of cholera in 
Trujillo was hypothesized, based on several facts: V 
cholerae 01 was isolated from municipal water samples, 
progressive contamination of municipal water during its 
distribution was observed, and high coliform counts were 
observed in samples taken from city wells to household 
storage containers. l3 Other studies conducted in Latin 
American countries identified both waterborne and food- 
borne transmission as welL20 
Household transmission of cholera was documented 
at the beginning of the epidemic in Peru21 Using a clini- 
cal definition of cholera, Gotuzzo et aJzl showed that 
16.8% of household contacts of index cases with micro- 
biologically confirmed cholera infection were infected in 
1991. Additionally, 50% of these cases presented at a local 
hospital for care and received intravenous fluid therapy. 
Another study conducted between November 1992 and 
Table 1. Risk Factors to Acquire Cholera Identified through Case- 
Control Studies Conducted during the Peruvian Cholera Epidemic 
Percentage of Risk Factor 
Risk Factor Cases Controls Odds Ratio 95% CI 
Drinking unboiled water 62 29.8 3.8 1.5-9.8 
59.2 27.7 3.1 1.3-7.3 
75 50 2.9 1.3-6.4 
Drinking stored water 44.0 21.3 2.9 1 .I-7.8 
31.8 8.6 4.2 1 s14.9 
Adding ice to beverages 87.5 62.8 4.0 1.04-l 6.6 
Drinking beverages 56.0 19.1 17.0 2.2-I 33.8 
from street vendors 
Eating from street 26.0 4.3 16.0 2.0-l 28.0 
vendors 
Eating unwashed fruits 26.0 5.0 8.0 2.2-28.9 
Eating cool leftover rice 38.0 22.0 2.1 1 .l-4.5 
32.0 17.8 3.3 0.7-6.2 
Drinking boiled water 62.0 91.5 0.1 0.02-0.5 
71.4 91.8 0.2 0.1-0.9 
Drinking acidic 52.0 77.0 0.4 0.2-0.7 
beverages 
Cl = confidence interval. Modified from Mujica et al,” with permission. 
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April 1993 in Lima showed rates of household transmis- 
sion significantly lower than those mentioned above.22 In 
that study, only 2% of household contacts of confirmed 
index cases acquired cholera. 
Why did cholera have such an explosive behavior in 
Peru? Several factors may explain the rapid spread of 
cholera throughout Peru and Latin America. 
The poor sanitary conditions and increased poverty 
prevalent in Peru and other neighboring countries 
during 1991. 
The high prevalence of 0 blood group among the 
South American population. A study conducted in 
Lima showed that patients with 0 blood group had 
a significant risk to present severe dehydration 
([relative risk] RR 4.8, 95% CI: 2.2-10.6).23 Similar 
observations have been made during the seventh 
cholera pandemic.** 
The association between infection by Helicobacter 
pylori and chronic gastritis. It has been recognized 
that infection by H. pylori is prevalent in developing 
countries, and that patients with chronic gastritis 
induced by this agent experience hypochlorhydria.2j 
As a consequence, hypochlorhydria puts them at 
increased risk to acquire bacterial enteropathogens. 
The association between infection by H. pylori and 
the risk to acquire cholera has been evaluated 
recently.26 The risk to acquire cholera was signifi- 
cantly higher among people infected by H. pylori 
(RR 1.61, 95% CI:1.07-2.42) and the risk of severe 
cholera was higher among people infected with H. 
pylori with no previous contact with Vcholerae (RFC 
2.88, 95% CI:1.28-6.48) as determined by negative 
serum vibriocidal test.26 The fact that infection by H. 
pylori with previous exposure to Rcholerae was pro- 
tective against severe cholera suggest that the 
increased risk to acquired severe cholera in patients 
with chronic gastritis due to H.pyZori may be over- 
come by using cholera vaccines.26 
Case fatality rates during the Latin American epidemic 
were the lowest reported during the seventh pandemic 
of cholera. The case fatality rate for Latin America was 
0.9% for the period 1991 to 1994.11,27 Peru had the low- 
est case fatality rate among all Latin American countries. 
A well-organized national response to the epidemic, 
extensive promotion of the use of oral rehydration ther- 
apy (ORT) throughout the country, adequate adminis- 
tration of fluids for replacement therapy even in remote 
places, and dedication of physicians and nurses through- 
out the country, with a special commitment to reduce 
the mortality to figures near zero, were responsible for 
such an excellent achievement.10~28 However, the expe- 
rience in the jungle of Peru, where high mortality rates 
were observed, underscores the necessity to train health 
care workers to adequately treat patients with cholera, to 
reinforce the use of ORT, but especially to establish 
regional treatment centers during epidemic situations.15 
In that study, the majority of deaths occurred at home 
within 36 hours after disease onset, and the use of ORT 
had been suboptimal. l5 The protective factor against mor- 
tality was to have received treatment by a health care 
worker with either ORT or intravenous fluids. 
Wbrio cholerae 01 El Tor serotype Inaba was respon- 
sible for this epidemic. The agent was similar to the R 
cholerae 01 that caused the seventh pandemic but dif- 
ferent from the agent responsible for small epidemics in 
North America and Australia.29 A shift in the serotype 
was observed after the first year of the epidemic from 
Inaba to the Ogawa serotype.16 Current evidence sup- 
ports the hypothesis that this epidemic was the result of 
the extension of the seventh pandemic more than due to 
mutation of non-01 or non-toxigenic 01 vibrios previ- 
ously isolated in Latin American countries.29 
The Eighth Pandemic of Cholera? 
In October 1992, cases of acute watery diarrhea clini- 
cally indistinguishable from the diarrhea caused by 
Rcholerae 01 were observed in Madras, India.4a30 The 
epidemic spread rapidly along the Bay of Bengal. To date 
11 countries have been affected in the region, and 
approximately 100,000 cases have been reported.11,31 
Imported cases in developed countries have also been 
reported. 9,32,33 Spread of 0139 cholera epidemic is illus- 
trated in Figure 3. This epidemic has a number of inter- 
esting features. 
1. It was caused by a non-01 Rcholerae, referred to as 
0139 or Bengal strain.34 Non-01 vibrios had been 
associated with small epidemics of watery diarrhea 
but never had shown pandemic potential. The rapid 
* Initial Epidemic 
October 1992 
- October 1944 
Figure 3. The spread of % cholerae 0139 epidemic in Asia, 
1992-1994. From Center for Disease Control,” with permission. 
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extension of this epidemic gained the attention of 
the scientific community, alerting for the possibility 
of a new pandemic of cholera.35 
2. Age groups affected by this new strain were differ- 
ent than those previously identified in India and 
Bangladesh, showing that no protection was con- 
ferred by previous exposure to Rcholerue 01, and 
that vaccines against 01 vibrios may not be effec- 
tive in controlling this epidemic30 
3. The clinical picture was similar to that produced by 
01 vibrios.36s37 The only direct comparison of the 
clinical picture and toxin production by 0139 and 
01 vibrios conducted in Dhaka, Bangladesh, showed 
that the disease produced by these two agents was 
clinically similar, but patients who acquired 0139 
cholera were less hypothermic, purged lower vol- 
umes of stools, and required lesser volumes of fluids 
to be rehydrated during the first 24 hours of ther- 
apy than 01-infected patients.38 However, these dif- 
ferences are clinically unimportant and do not help 
to differentiate between these two infections. Both 
serum and stool electrolyte concentrations, as well 
as acid-base abnormalities were similar in Ol- and 
013Pinfected patients in that study. These obser- 
vations confirm the initial impression of similar clin- 
ical pictures produced by these two vibrios. 
4. Molecular epidemiologic tools have shown that this 
novel agent is closer to El Tor Rcholerae 01 than to 
other non-01 vibrios, and it is totally different from 
01 strains isolated from North America and Aus- 
tralia.39,40 Although different ribotypes have been 
observed among Asiatic strains, the meaning of that 
finding is not clear.*l 
5. The new agent was resistant to cotrimoxazole, but 
sensitive to tetracyclines. In contrast, 01 Kcholerae, 
endemic in India and Bangladesh before the appear- 
ance of this novel vibrio was resistant to tetracyclines 
and trimethoprim-sulfamethoxazole, but sensitive to 
erythromycin. Because it was not possible to distin- 
guish clinically the infection produced by these two 
vibrios, erythromycin was the antimicrobial of choice 
to treat cholera in Bangladesh during the epidemic. 
6. The epidemic had subsided in Bangladesh by the end 
of 1994; few cases are being reported. Once again, 
01 vibrios are prevalent in India and Bangladesh. 
This new epidemic has stressed the need of main- 
taining continuous surveillance across the world to detect 
changes in the etiologic and epidemiologic features of 
cholera.33 It also has demonstrated the limited utility of 
current cholera vaccines to control this epidemic. 
Recent Cholera Epidemics in Zaire 
Following a massive migration of Rwandan Hutus to Zaire 
after a political crisis in July 1994, a huge epidemic of 
cholera ensued.* The first case of cholera was identified 
on July 20, 1994. El Tor Rcholerae 01, resistant to tetra- 
cyclines, was isolated from patients with acute watery 
diarrhea in Zaire. During the next 4 weeks, the world 
observed what has probably been the worst epidemic of 
cholera during this century, and definitely the epidemic 
with the highest attack and case fatality rates ever 
reported.2 The estimated number of cholera cases ranged 
between 50,000 and 80,000, with attack rates between 
7.3% and 16%, according to population estimates. Crude 
mortality rates from July 14 to August 14 ranged between 
19.5 and 31.2 per 10,000 habitants. Approximately 88% 
of deaths were caused by diarrhea1 diseases, and 57% of 
them were due to cholera. The city of Coma was the 
most severely affected. Factors associated with mortality 
were similar to those identified during the epidemic of 
cholera in the jungle of Peru.** Lessons learned from this 
epidemic were: 
1. Diarrhea1 diseases, including cholera and shigellosis, 
can produce dramatic epidemics with high case fatal- 
ity rates. 
2. Observation of warning systems should not be 
ignored by decision-making authorities. 
3. Significant improvement of emergency preparedness 
should be made to deal with future disasters.2 
CLINICAL AND THERAPEUTIC ASPECTS 
The hallmark of cholera is a profuse secretory diarrhea 
induced by an enterotoxin secreted by either Rcholerae 
01 or, more recently, by K cholerae 0139. That entero- 
toxin, commonly referred to as cholera toxin, does not 
produce intestinal inflammation, but instead produces 
secretion to the intestinal lumen of huge amounts of elec- 
trolytes, mainly sodium and chloride as well as bicar- 
bonate, resulting in dehydration ranging from mild to 
severe, and metabolic acidosis especially in severely dehy- 
drated patients. At least three other toxins secreted by V 
cholerae 01 have been identified, but their role in the 
pathogenesis of the disease is not fully understood.6 
The dehydration that this enterotoxin produces is 
isotonic; the stool electrolyte concentrations are similar 
to those of serum. Hence, treatment is aimed at replac- 
ing these electrolytes plus water, using fluids with simi- 
lar concentrations to those lost as a result of diarrhea 
and vomitus. If adequate replacement of electrolytes and 
water can be ensured rapidly, mortality associated with 
cholera should be near zero. Recent experience with 
cholera epidemics in Latin America and Africa summa- 
rized above, have shown low case fatality rates in the 
former, but incredibly high figures in the later. Factors 
responsible for such a difference have been delineated 
above, with difference in the quality of care and scarcity 
of resources as the main reasons. 
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Table 2. Clinical Findings in Patients with Cholera according to Degree of Dehydration 
Finding Mild Dehydration Moderate Dehydration Severe Dehydration 
Loss of fluid < 5% 5-10% > 10% 
Mentation Alert Restless Drowsy or comatose 
Radial pulse 
Rate Normal Rapid Very rapid 
Intensity Normal Weak Feeble or impalpable 
Respiration Normal Deep Deep and rapid 
Systolic blood pressure Normal Low Very low or unrecordable 
Skin elasticity Retracts rapidly Retracts slowly Retracts very slowly 
Eyes Normal Sunken Very sunken 
Voice Normal Hoarse Not audible 
Urine production Normal Scant Absent 
From Bennish,@ with permission from the publisher. 
Clinical symptoms and signs according to the degree 
of dehydration are presented in Table 2. The first step in 
the evaluation of a cholera case is to estimate properly 
the degree of dehydration. This evaluation can be per- 
formed by any health care worker with supervised train- 
ing by experienced physicians. Current recommended 
solutions to rehydrate patients with cholera are presented 
in Table 3. Specific recommendations to rehydrate 
patients with cholera have been extensively reviewed 
elsewhere,43,44 and practical guidelines relevant to devel- 
oping countries recently have been discussed.45 A sum- 
mary of these recommendations is presented in Table 4. 
The use of ORT cannot be overemphasized. The 
recent experience in Peru in both children and adults 
shows clearly how a scientific discovery can be so suc- 
cessfully applied at bedside to reduce mortality under 
epidemic conditions. 1o,46 
Antimicrobial Therapy 
Whereas treatment of dehydration is easy to accomplish 
and represents the mainstay of cholera treatment, the use 
of antimicrobials is only adjunctive to rehydration ther- 
apy. Antimicrobial agents have been shown to reduce the 
duration of disease, to shorten the volume of stools by 
Table 3. Electrolyte Concentration of Cholera Stools and 
Common Solutions Used for Treatment 
Electrolyte and Glucose 
Concentration (mmol/L) 
Na+ C/P K’ HCO, 
Cholera stool 
Adults 130 100 20 44 
Children 100 90 33 30 
Intravenous solutions 
Ringer’s lactate 130 109 4 28* 
Dhaka 133 98 13 48 
Normal saline 154 154 0 0 
Peru polyelectrolyte 90 80 20 30 
WHO ORT 90 80 20 30+ 
*Ringer’s lactate does not contain HCO, but, instead, lactate; +Bicar- 
bonate is replaced with trisodium citrate, which persists longer than 
bicarbonate in sachets. 
ORT = oral rehydration therapy. 
half, and to reduce the excretion of vibrios to the envi- 
ronment.44~47~48 In recent years, however, the selection of 
effective drugs has been complicated due to the appear- 
ance worldwide of resistant strains.3,49,j0 Improper use of 
antimicrobials to treat infectious diseases in developing 
countries, the lack of control programs to avoid non-physi- 
cian prescription of antimicrobials, and the massive use 
of prophylaxis in some countries in an attempt to control 
cholera spread have been responsible for this phenome- 
non. This situation has prompted the search for adequate 
alternatives to treat these resistant strains. Currently, ery- 
thromycin is the first choice to treat cholera caused by R 
cholerae 01 in Bangladesh, and pivamdinocillin is the 
antimicrobial of choice to treat shigellosis in that country.** 
However, the appearance of resistant strains to these 
antimicrobials is anticipated. 
Among the new antimicrobial agents to treat cholera, 
the fluoroquinolones are probably the group most exten- 
sively studied. A summary of relevant results from these 
studies is presented in Table 5. Several quinolones have 
been tested against cholera, including norfloxacin,51,52 
lomefloxacin,53 and ciprofloxacin.54-59 Ciprofloxacin has 
been the quinolone most extensively tested in cholera. 
Three open studies have been conducted in Peru and 
Table 4. Practical Guidelines for the Treatment of Cholera 
1. Evaluate the degree of dehydration on arrival. 
2. Rehydrate the patients in two phases: 
a. Rehydration phase: lasts 2-4 hours. 
b. Maintenance phase: lasts till diarrhea abates. 
3. Register output and intake volumes in pre-designed charts and 
review the data collected periodically. 
4. Use the intravenous route only to rehydrate: 
a. Severely dehydrated patients during the rehydration phase, in 
whom an infusion rate of 50-l 00 ml/kg/h is advised. 
b. Moderate patients who do not tolerate the oral route. 
c. High stool purges (>I 0 ml/kg/h) during the maintenance 
phase. 
5. Use ORT for patients during the maintenance phase at a rate of 
800-l 000 cc/h, matching ongoing losses with ORT. 
6. Discharge patients to the treatment center if the following 
conditions are fulfilled: 
a. Oral tolerance >lOOO cc/h, 
b. Urine volume 240 mVh, and 
c. Stool volume 5400 mUh. 
ORT = oral rehydration therapy. Modified from Seas et al,45 with permission. 
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Table 5. Summary of Results from Clinical Trials Using Fluoroquinolones in Cholera 
Quinolone 
Norfloxacin 
Study Design 
I. Randomized, double- 
blind, and controlled5’ 
Dosing Regimens 
a. Norfloxacin, 400 mg bid, 3 d 
Number 
of Patients 
13 
b. TMPSMX, 1601800 mg 12 
Duration Clinical 
of Diarrhea Cure 
Mean Hours (SD) n (%) 
19.2 (4.4) NS 
27.5 (4.0) 
29.3 (4.5) 
60.8 (18.4) 
91.04 (50.1) 
61.66 (23.2) 
49.6 (16.9) 
53.6 (14) 
48.3 (14.4) 
NS 
NS 
51.2 (17.4) 
48.0 (20.6) 
NS+ 
NS 
41 (19) 
NS+ 
NS 
Bacteriologic 
Cure 
n (%) 
NS 
NS 
NS 
2. Open, randomized, 
and controlledsz 
Lomefloxacin Open, non-controlled53 
Ciprofloxacin 1. Open, non-controlled54 
2. Open, non-controlled54 
3. Open, randomized, 
and controlled55 
4. Randomized, double- 
blind, and controlled56 
5. Randomized, double- 
blind, and controlled57 
bid, 3 d 
c. Placebo 
a. Norfloxacin, 400 mg bid, 3 d 
b. Norfloxacin, 800 mg single-dose 
c. Tetracycline, 500 mg qid, 3 d 
400 mg once per day, 3 d 
500 mg bid, 3 d 
250 mg bid, 3 d 
a. Ciprofloxacin, 500 mg bid, 3 d 
b. Tetracycline, 500 mg qid, 3 d 
a. Ciprofloxacin, 250 mg 
once-a-day, 3 d 
b.Tetracycline, 500 mg qid, 3 d 
a. Ciprofloxacin, 1 g single-dose 
b. Doxycycline, 300 mg single-dose 
6. Open, non-randomized E* Ciprofloxacin, 1 g single-dose 
7. Randomized, double- a. Ciprofloxacin, 1 g single-dose 
blind, and controlled§5g b. Doxycycline, 300 mg single-dose 
12 
25 
34 
35 
68 
20 
21 
15 
12 
100 
102 
66 
64 
16 
59 
70 
NS 
25 (74) 
13 (52) 
27 (77) 
61 (90) 
18 (90) 
19 (90) 
14 (93) 
5 (42) 
84 (84) 
91 (89) 
62 (94) 
47 (73) 
NS 
54 (91.5) 
64 (91.4) 
3N4qloo) 
19 (76) 
31 (91) 
48 (100) 
20 (100) 
21 (100) 
15 (100) 
6 (50) 
99 (99) 
97 (95) 
63 (95) 
44 (69) 
NS* 
58 (98) 
55 (79) 
*Patients in the ciprofloxacin group had shorter duration of diarrhea than patients in the tetracycline group (Kaplan-Meier survival curve, P = 0.004 by log-rank test); 
Ciprofloxacin group had shorter duration of diarrhea than single-dose doxycycline group in V cholerae 01 -infected patients, but not in !/ choierae 0139-infected 
patients (Kaplan-Meier survival curve, P = 0.0451 and P = 0.435 by log-rank test, respectively): *Diarrhea stopped in all patients within 72 hours of therapy. Stool 
cultures were neaative for 1! cholerae 0139 durina the third dav of theraov: Ftudies conducted in !L cbolerae 0139.infected oatients. 
TMP/SMX = trirn~thoprim-sulfarnethoxazole; NS = not specified. . 
Bangladesh using ciprofloxacin at different dosing regi- 
mens: two studies were conducted in patients with 
severe cholera due to Rcholerae 01 El Tor,54,5j and one 
study in severe cholera caused by 0139 K choZerae.58 
Additionally, three randomized and double-blinded stud- 
ies using single daily dose or single dose (1 g) have been 
conducted.5G~57~59 
Data from these well-conducted studies show clearly 
that the quinolones are equally as effective as the stan- 
dard therapy (multiple dose tetracycline regimen or single- 
dose doxycycline regimen) in all clinical parameters (i.e., 
duration of diarrhea, fluid requirements for rehydration, 
and total volume of stools) but attained earlier eradica- 
tion of the bacterium from the stools. The early eradica- 
tion of R cholerae from the stools of a patient with 
cholera may reduce the household transmission of the 
disease and may help in controlling its spread. This 
hypothesis merits further evaluation especially under epi- 
demic conditions. 
Recent pharmacokinetic studies conducted in patients 
with diarrhea due to Kcholerae 0139 and Shigella spp 
treated with single-dose ciprofloxacm (1 g) in Bangladesh, 
provide adequate explanation for the excellent results 
observed in the trials discussed above.60 Stool concentra- 
tions of ciprofloxacin were more than 200 times higher 
than the minimal inhibitory concentration (MIC) of R 
cholerae 0139 after 48 hours of therapy, values for 
Shigella spp-infected patients were even higher than those 
reported for Kcholerae. Biliary excretion, transepithelial 
secretion, and reduced absorption of ciprofloxacin may 
explain these high stool concentrations.60 
Current available data favor the use of quinolones as 
an alternative choice to tetracycline and erythromycin 
to treat severe cholera. The use of quinolones should be 
restricted to the management of severe cholera and 
shigellosis in areas where resistant strains to common 
antimicrobials are prevalent, because its extensive use to 
treat any infectious diarrhea may cause the appearance 
of resistant strains, as has occurred with many antimi- 
crobials in developing countries. Disadvantages of the 
fluoroquinolones are their high cost and the potential 
toxicity to the growing cartilage in humans that precludes 
its use in pregnant women and in children. Although 
there is no compelling evidence that this toxicity could 
be present in humans, the use of fluoroquinolones in 
children is still not recommended. Among the quinolones 
evaluated, the authors recommend ciprofloxacin either 
in a single dose (1 g) or 250 mg once-a-day for 3 days, as 
the best choices. 
PREVENTIVE ISSUES 
The recent epidemics of cholera in South America, Africa, 
and Asia have stressed the necessity of implementing and 
reinforcing global programs to control cholera and other 
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diarrheal diseases. The ability of Rcholerae to survive in 
the environment even at nondetectable levels for standard 
microbiologic techniques, 61 the appearance of new vib- 
rios with pandemic potential,* and the extremely poor san- 
itary and hygienic conditions existing in many developing 
countries around the globe, predict that cholera control 
will be very difficult if not impossible by the year 2000. 
It is clear from these epidemics that by providing 
safe drinking water, ensuring adequate disposal of exc- 
reta, and changing hygienic practices of the population 
at risk, it is possible to control the transmission of cholera 
and other diarrhea1 diseases. On the other hand, it is also 
evident that to implement these measures a political deci- 
sion and investment of significant financial resources are 
necessary.‘O Two alternative ways to control the spread 
of cholera should be mentioned: the use of vaccines and 
mass chemoprophylaxis with antimicrobials. 
The ideal vaccine against cholera still is not available. 
This vaccine should be administered in a single oral dose, 
should induce a prompt and lasting immunologic 
response, should be well tolerated, and most importantly, 
its cost should be reasonable and affordable for devel- 
oping countries. An oral inactivated vaccine that con- 
tains killed Rcholerae plus B subunit has been extensively 
evaluated in developing countries, including Bangladesh 
and Peru.62,63 Three-year evaluation of this vaccine in 
Matlab, Bangladesh showed that overall protective effi- 
cacy was near 50%, but the population at significant risk, 
children 2 to 15 years of age, were not adequately pro- 
tected. This vaccine has the disadvantage of requiring 
multiple doses to achieve protection. However, recent 
evaluations suggest that two doses are enough to confer 
protection. Live attenuated cholera vaccines are perhaps 
closer to the ideal vaccine delineated above than inacti- 
vated vaccines. The experience in Peru with a third gen- 
eration vaccine, CVD 103 HgR, suggests that significant 
protection can be attained with this vaccine under epi- 
demic conditions.64 A recent extensive review of selected 
studies conducted using this vaccine confirms that appre- 
ciation.65 The predominance of type 0 blood in the Latin 
American population has raised the question of lower 
immunogenicity to current vaccines in people carrying 
this blood group. A recent evaluation conducted in Chile 
with the live attenuated cholera vaccine CVD 103 HgR, 
showed that children 5 to 9 years old who have type 0 
blood had significantly higher mean geometric titers than 
children with non-0 blood group (486 and 179, respec- 
tively, P < 0.02) but rates of seroconversion were inde- 
pendent of the blood gro~p.~~ These fmdings suggest that 
this vaccine may represent a significant advance in the 
fight against cholera; results from field evaluation of effi- 
cacy and safety are awaited with enthusiasm. However, 
the appearance of Rcholerue 0139, for which previous 
exposure to 01 vibrios does not confer protection, raises 
the doubt about the utility of current investigated vac- 
cines against new emerging pathogens. 
The use of antimicrobials as a prophylactic measure 
against cholera has proven historically not to control the 
spread of the disease. 67 Prophylactic agents may be rec- 
ommended under conditions of high transmission rates, 
for instance, during the devastating epidemic of cholera 
in Zaire during July and August 1994, where attack rates 
of nearly 22% were reported at the peak of the epidemic. 
The use of this measure when the rate of transmission of 
the disease is low is not advised, even using fluoro- 
quinolones.22 Problems associated with massive use of 
antimicrobial prophylaxis are the potential induction of 
resistant strains, the induction of potential serious side 
effects, and the feeling of complete protection by users. 
Another important problem is how to control its admin- 
istration to only high-risk populations in developing coun- 
tries, where self-prescription of antimicrobials is highly 
common. 
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